 Aims: The aims of this study are to determine a the differences in neuroendocrine and metabolite substrates between patients diagnosed with schizophrenia and healthy controls; and b the associations among the neuroendocrine and metabolite substrates, cognitive function, clinical symptoms, and treatment responses of patients diagnosed with schizophrenia. 